Article thumbnail

Functional Role of Kallikrein 6 in Regulating Immune Cell Survival

By Isobel A. Scarisbrick, Benjamin Epstein, Beth A. Cloud, Hyesook Yoon, Jianmin Wu, Danielle N. Renner, Sachiko I. Blaber, Michael Blaber, Alexander G. Vandell and Alexandra L. Bryson
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3065477
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). 1.70 A X-ray structure of human apo kallikrein 1: structural changes upon peptide inhibitor/substrate binding.
  2. (2003). A
  3. (1996). A novel protease homolog differentially expressed in breast and ovarian cancer.
  4. (2004). A role for proteinase-activated receptor-1 in inflammatory bowel diseases.
  5. (2002). Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim.
  6. (2002). Activity of a newly identified serine protease in CNS demyelination.
  7. (2002). BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes.
  8. (2009). Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.
  9. (2004). Caspase cleavage of BimEL triggers a positive feedback amplification of apoptotic signaling.
  10. (1997). Caspases: the executioners of apoptosis.
  11. (1987). Cell growth cycle block of T cell hybridomas upon activation with antigen.
  12. (2008). Coexpression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma.
  13. (1997). Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapyinduced apoptosis is not dependent on Fas/Fas ligand interactions.
  14. (2002). Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system.
  15. (2002). Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer’s disease.
  16. (2002). Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer’s disease patients.
  17. (1994). Determination of lymphocyte division by flow cytometry.
  18. (1993). Dexamethasone-induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation.
  19. (2003). Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells.
  20. (2004). Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease.
  21. (2006). Dynamic role of kallikrein 6 in traumatic spinal cord injury.
  22. (2002). Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear.
  23. (2002). Enzymatic properties of rat myelencephalon-specific protease.
  24. (2003). Essential role for proteinase-activated receptor-2 in arthritis.
  25. (2000). Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma.
  26. (2004). Human tissue kallikreins: physiologic roles and applications in cancer.
  27. (2006). Induction of IL-6 release from monocytes by serine proteinases and its potential mechanisms.
  28. (2003). JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis.
  29. (2006). Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs).
  30. (2008). Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration.
  31. (2009). KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
  32. (2003). Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulationinduced apoptosis and deletion of autoreactive B cells.
  33. (2009). Mitochondrial cell death effectors.
  34. (2000). Molecular mechanism of staurosporine-induced apoptosis in osteoblasts.
  35. (1997). Nervous system specific expression of a novel serine protease: regulation in the adult rat spinal cord by excitotoxic injury.
  36. (2005). PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism.
  37. (2003). PARticipation in inflammation.
  38. (2006). Potential scope of action of tissue kallikreins in CNS immune-mediated disease.
  39. (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity.
  40. (1990). Programmed T lymphocyte death. Cell activation- and steroid-induced pathways are mutually antagonistic.
  41. (2008). Protease Activated Receptor Dependent and Independent Signaling by
  42. (2009). Protease Activated Receptor-1 down-regulates the murine inflammatory and humoral response to Helicobacter pylori.
  43. (2000). Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis.
  44. (2006). Protease-activated receptor-1 protects rat astrocytes from apoptotic cell death via JNK-mediated release of the chemokine GRO/CINC-1.
  45. (2003). Protease-activated receptor-2 signaling triggers dendritic cell development.
  46. (1994). Protease-dependent T cell activation: ligation of effector cell protease receptor-1 (EPR-1) stimulates lymphocyte proliferation.
  47. (2009). Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2.
  48. (2006). Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.
  49. (2006). Proteinase-activated receptors, targets for kallikrein signaling.
  50. (2005). Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response.
  51. (2008). Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets.
  52. (2005). Reduction of arthritis severity in protease-activated receptor-deficient mice.
  53. (2008). Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity.
  54. (1993). Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.
  55. (2004). Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways.
  56. (2010). Stochastic models of lymphocyte proliferation and death.
  57. (2006). Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects.
  58. (2004). Targeting kallikrein 6-proteolysis attenuates CNS inflammatory disease.
  59. (2001). The expanded human kallikrein (KLK) gene family: genomic organization, tissue-specific expression and potential functions.
  60. (2000). The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes.
  61. (2003). Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1.
  62. (2003). Tryptase activates peripheral blood mononuclear cells causing synthesis and release of TNF-a, IL-6 and IL-1B: possible relevance to multiple sclerosis.